Clinical Trials Browser

Phase 2 × Interventional × Lethal Congenital Contracture Syndrome 2 × Clear all

NCT02912949 2025-04-29

A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)

Phase 2 Active not recruiting

250 enrolled 1 FDA

GastrointestinalThoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms

NCT03321981 2024-03-07

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

Phase 2 Completed

105 enrolled 23 charts

Lethal Congenital Contracture Syndrome 2